BJERKHOLT ERIC 4

What Happened

• Eric Bjerkholt, CFO of Mirum Pharmaceuticals, had 13,334 performance restricted stock units (PRSUs) convert/vest on March 15, 2026 (reported as an exercise/conversion of a derivative with no cash paid). Following the vesting, he sold 7,287 shares in an open-market transaction on March 16, 2026 at $91.98 per share, generating proceeds of $670,243. The filing also shows a related derivative disposition of 13,334 shares at $0, consistent with conversion/settlement of the PRSUs.

Key Details

• Transaction dates and prices:
  • 2026-03-15: Conversion/exercise of 13,334 PRSUs into common stock (derivative conversion, no cash paid).
  • 2026-03-16: Open-market sale of 7,287 shares at $91.98 each, proceeds $670,243.
• Footnotes:
  • F1: Each PRSU converts into one share of common stock.
  • F2: Shares were sold to cover tax withholding obligations tied to the vesting of the PRSUs.
  • F3: Vesting schedule: 2/3 vested on March 15, 2026 and remaining 1/3 vests on March 15, 2027 (the 13,334 shares correspond to the 2/3 tranche).
• Shares owned after the transactions are not specified in the provided excerpt.
• Filing: Report filed with the SEC on March 17, 2026 covering the March 15 transactions; timing appears to be within the normal Form 4 reporting window (not marked late).

Context

• These entries reflect vesting/settlement of PRSUs and a subsequent sell-to-cover/open-market sale to satisfy tax withholding—common executive-side activity that is typically routine rather than a direct bullish signal. The derivative lines simply record conversion/settlement of the performance awards into common stock prior to the sale.